<div>Protein N-terminal methyltransferases (NTMTs) are a family of enzymes that methylate the α-N-terminus of a variety of protein substrates. Both NTMT1 and NTMT2 recognize a unique N-terminal X-P-K/R motif (X represents any amino acid other than D/E) to install 1-3 methyl group(s) on the substrates. NTMT1 plays important roles in mitosis regulation, chromatin interactions, and DNA damage repair. Another member NTMT2 shares ~50% sequence similarity and the same substrate recognition motif although NTMT2 was initially characterized as a mono-methyltransferase. To understand the molecular mechanism of NTMT2, we obtained the first co-crystal structure of NTMT2 in complex with its peptide substrate. After an extensive investigation of substrate recognition and methylated products of NTMT1/2, we found out that NTMT2 can fully methylate G/P-PKRIA peptides despite a predominant mono-methyltransferase. Moreover, we identified a gatekeeper N89 in NTMT2 that controls the substrate entry and the product specificity of NTMT2.</div><div>To elucidate the biological functions of NTMT1/2-catalyzed N-terminal methylation, we applied two different strategies to discover cell-potent inhibitors. Guided by the co-crystal structures of NTMT1 in complex with previously reported inhibitors, we designed and synthesized a series of new peptidomimetic inhibitors. By introducing more hydrophobic groups, the most cell-potent peptidomimetic inhibitor GD562 (IC50 = 0.93 ± 0.04 µM) exhibited over 2-fold increased inhibition on cellular N-terminal methylation levels with an IC50 value of ~50 µM compared to previously reported peptidomimetic inhibitor DC541. Meanwhile, we also discovered the first potent small molecule inhibitor Genz-682452 (IC50 = 0.5 ± 0.04 µM) after screening ~58,000 compounds. Subsequent structural modifications led to the discovery of GD433 (IC50 = 27 ± 0.5 nM) with a 20-fold increased potency compared to the initial hit Genz-682452. Inhibition mechanism indicated both inhibitors bind to peptide-binding pocket and co-crystal structures of both Genz-682452 and GD433 with NTMT1 confirmed their binding modes. Furthermore, GD433 shows over 7-fold selectivity over other major 40 protein methyltransferases and DNA methyltransferase and exhibits improved selectivity for NTMT1 over glucosylceramide synthase (GCS). GD433 significantly decreases the cellular N-terminal methylation level of NTMT1 substrates RCC1 and SET at 10 nM in both HEK293 and HCT116 cells, providing a valuable probe for cell-based studies in the future.<br></div><p><br></p>

La plasticité cérébrale pathologique qui se met en place en réponse à l'administration répétée de drogue nécessite des modifications de l’expression des gènes, au moyen,entre autres, de mécanismes épigénétiques tels que la méthylation de l’ADN. Dans ces travaux, nous avons montré que l’inhibition des ADN méthyl transférases par la 5-aza-2’-désoxycytidine augmentait les propriétés renforçantes de la cocaïne dans un protocole d’auto-administration intraveineuse, et ce, sans affecter la motivation des rats pour la cocaïne, ni la réactivation du comportement de recherche après une période de sevrage.L’analyse du méthylome dans le cortex préfrontal médian nous a permis de caractériser près de 190000 régions génomiques différentiellement méthylées suite au traitement par la cocaïne, en association ou non avec la 5-aza-2’-désoxycytidine. Nous avons sélectionné une vingtaine de régions situées soit dans les promoteurs soit au sein de gènes participant à la plasticité neuronale. L’analyse de la transcription de ces gènes a permis, pour certains d’entre eux, de corréler les variations de méthylation avec celles d’expression, comme dans le cas du gène Hdac2. / Repeated drug administration lead to pathological brain plasticity that requires modifications of gene expression through, among others, epigenetic mechanisms such DNA methylation. Here, we showed that DNA methyltransferases inhibitors such 5-aza-2’-deoxycytidine increase reinforcing properties of cocaine in an intravenous self administration paradigm without affecting the motivation of rats for the drug, nor drug seeking after withdrawal. The analysis of the methylome in the medial prefrontal cortex allowed us to identify approximatively 190000 differentially methylated genomic regions in response to cocaine treatment, in association or not with 5-aza-2’-deoxycytidine. We selected around twenty regions within promoters or body of genes known to participate in neuronal plasticity. The study of the transcription of these genes permitted for some of them to correlate the modifications of the DNA methylation with the modifications of the expression, like, for example, in the case of the gene Hdac2.